A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

October 31, 2009

Conditions
Gaucher Disease
Interventions
DRUG

Plant cell expressed recombinant glucocerebrosidase (prGCD)

Intravenous infusion every two weeks for 9 months

DRUG

Plant cell expressed recombinant glucocerebrosidase (prGCD)

Intravenous infusion every 2 weeks for 9 months

Trial Locations (11)

2196

Morningside Medi-Clinic, Morningside

10016

New York University Medical Center, New York

30033

Division of Medical Genetics, Emory University School of Medicine, Decatur

31096

Rambam Medical Center, Haifa

33065

University Research Foundation for Lysosomal Storage Diseases, Coral Springs

50009

Hospital Universitario Miguel Servet, Zaragoza

91031

Shaare Zedek Medical Center, Jerusalem

M5G 1X5

Mount Sinai Hospital, Toronto

Unknown

Pontificia Universidad Catolica de Chile, Santiago

00161

"Universita La Sapienza", Rome

NW3 2QG

Royal Free Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY